Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17. by Valenciano, Marta et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/irv.12562 
This article is protected by copyright. All rights reserved. 
DR. MARTA  VALENCIANO (Orcid ID : 0000-0002-2056-1062) 
MS. E  KISSLING (Orcid ID : 0000-0001-7188-8404) 
DR. AMPARO  LARRAURI (Orcid ID : 0000-0002-1704-2245) 
MISS AUSENDA  MACHADO (Orcid ID : 0000-0002-1849-1499) 
 
Article type      : Original Article 
 
Corresponding author mail id :  m.valenciano@epiconcept.fr 
Title 
Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine 
effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-
negative case-control study, 2011/12-2016/17. 
 
Running head : Previous influenza vaccination, I-MOVE 2011-2017  
 
Abstract 
Background 
Results of previous influenza vaccination effects on current season influenza vaccine effectiveness 
(VE) are inconsistent.  
Objectives 
To explore previous influenza vaccination effects on current season VE among population targeted 
for vaccination.  
 
 
Methods 
We used 2011/12 to 2016/17 I-MOVE primary care multicentre test-negative data. For each season 
we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in 
previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between 
vaccinated in: both seasons, current only, and previous only.  
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Results 
We included 941, 2645 and 959 influenza like illness patients positive for influenza A(H1N1)pdm09, 
A(H3N2), and B, respectively and 5532 controls. In 2011/12, 2014/15, 2016/17 A(H3N2) aVE point 
estimates among those vaccinated in previous season, were -68%, - 21% and -19% respectively; 
among unvaccinated in previous season 33%, 48%, 46% respectively (aVE not computable for 
influenza A(H1N1)pdm09 and B).  
Compared to current season vaccination only, VE for both seasons vaccination was a) similar in two 
of four seasons for A(H3N2) (absolute difference (ad)  6%, 8%); b) lower in three of four seasons for 
influenza A(H1N1)pdm09 (ad 18%, 26%, 29%),  in two seasons for influenza A(H3N2) (ad  27% , 39%), 
in two of three seasons for influenza B (ad 26% and 37%);  c) higher in one season for influenza 
A(H1N1)pdm09 (ad 20%),  and influenza B (ad 24%).  
Conclusions 
We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies 
documenting influenza infections, vaccinations, vaccine types, are needed to understand previous 
influenza vaccinations´ effects. 
 
Introduction 
Constant evolution of influenza viruses requires possible reformulation of the influenza vaccine every 
season. In February each year, the World Health Organization (WHO) organises a technical 
consultation to decide which influenza strains to be included in the Northern Hemisphere seasonal 
influenza vaccines (1).  
Most groups for whom the seasonal influenza vaccine is recommended may receive a trivalent or 
quadrivalent inactivated seasonal influenza vaccine annually irrespective of their previous influenza 
virus infections or influenza vaccination history. In children less than 9 years old, one dose of 
inactivated influenza vaccine is recommended for children vaccinated in previous season and two 
doses for those previously unvaccinated (2). 
Several observational studies and meta-analyses have reported inconsistent results of the effect of 
previous vaccination on current season influenza vaccine effectiveness (VE) (3–12). Some suggest 
that previous vaccination may reduce the effectiveness of vaccination in the current season (3,5,6). 
Various explanations were proposed. The original “antigenic sin” hypothesis suggests that 
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vaccination primarily boosts pre-existing antibody responses that cross-react with the vaccine strain 
rather than producing a de novo response to the vaccine or infecting strain (13). The “antibody 
block” hypothesis suggests that previously vaccinated individuals do not have the cross-protective 
immunity provided by natural infection (14,15). According to the “antigenic distance”and hypothesis, 
in seasons when similar strains are included in the subsequent vaccines but are different from the 
circulating strain, previous vaccination may negatively interfere with current vaccination (16). Finally, 
because the influenza vaccine is recommended to individuals with high risk conditions (e.g. pregnant 
women, persons with chronic conditions, older adults aged >59 or > 64 years), characteristics of 
individuals repeatedly vaccinated may result in a poorer observed response to the vaccine if we fail 
to control for negative confounding (4).  
Due to the frequent changes of the genetic and antigenic characteristics of the circulating influenza 
strains and of those included in the vaccines, data from multiple seasons are needed to measure the 
potential effects of previous vaccinations and to explore the possible mechanism(s) that may explain 
such effects (11).  
In this article, using the I-MOVE primary care multicentre case-control study (MCCS) data, we 
present, influenza type/subtype-specific VE stratified by previous season vaccination among the 
target groups for vaccination for each of the 2011/12 to 2016/17 seasons. Additionally, using those 
unvaccinated in both seasons as a reference group, we calculated VE for different combinations of 
previous/current vaccination among the target population for vaccination (indicator analysis).  
Both analyses measure the effect of current vaccination among those not vaccinated in the previous 
season. The indicator analysis additionally gives information on the potential residual protection of 
the previous season vaccination and the combined protection of current and previous season 
vaccination, compared to the reference group. This reference group “unvaccinated in both seasons” 
may consist of a population that is quite different from the other categories of individuals who have 
been vaccinated, making controlling for confounding challenging (11). Therefore we present also the 
stratified analysis, where the stratum of those with previous vaccination indicates the extra 
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protection the current vaccination may have, compared to residual effects of previous vaccination, 
while controlling adequately for previous vaccination history.  
 
Methods 
Each season we conducted a primary care based test-negative design MCCS. The methods were 
described previously and are based on the same generic study protocol (17).  
In summary, practitioners from twelve participating sites interviewed a systematic sample of patients 
consulting for influenza like illness (ILI, EU case definition: sudden onset of symptoms and at least 
one of the following systemic symptoms: fever or feverishness, malaise, headache, myalgia, and at 
least one of the following respiratory symptoms: cough, sore throat, shortness of breath) and 
collected naso-pharyngeal specimens for virological analyses. The data collected include ILI 
symptoms and date of onset, age, sex, presence of chronic conditions and hospitalisation for the 
chronic conditions in the previous 12 months. 
Vaccination status for current (including date of vaccination and type of vaccine used) and previous 
season were documented either through patients’ self-report or extracted from practitioners’ 
vaccine registries.  
We defined patients as vaccinated in the current season if they had received at least one dose of 
influenza vaccine more than 14 days before symptom onset. All others with information on current 
vaccination status were defined as unvaccinated. Patients who received at least one dose of 
influenza vaccine in the previous season were defined as vaccinated in the previous season. For this 
analysis we used the population for which influenza vaccination is recommended every season, as 
they are likely to be a more homogeneous group in terms of vaccination practices than those for 
whom vaccination is not recommended. They include older adults (aged over 54, 59 or 64 years 
depending on study site), individuals with chronic conditions and where available other groups for 
whom the vaccine was recommended in a given country (e.g. pregnant women, healthcare workers 
and other professional groups, depending on the study site). We excluded children aged less than 9 
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years as the definition of their current season vaccination status depends on their previous season 
vaccination.  
Cases were ILI patients testing positive for any type/subtype specific influenza virus using real-time 
reverse-transcription PCR (RT-PCR). Controls were those testing negative for all influenza viruses. 
Study periods depended upon season- and site-specific influenza virus type/subtype circulation and 
vaccination campaigns.   
We included ILI patients who consulted their practitioner more than 14 days after the start of 
national or regional seasonal influenza vaccination campaign (18), who were swabbed less than eight 
days after ILI symptom onset and who did not receive influenza antivirals before swabbing. We 
excluded patients with missing information for current or previous season vaccination status.  
We used logistic regression to compute the odds ratio (OR) of being vaccinated in cases and controls. 
We estimated the type/subtype adjusted influenza VE as (1 - OR)*100. Study site was modelled as a 
fixed effect and always included in the crude and adjusted analysis models. We measured VE carrying 
out a complete case analysis excluding patients with missing values for any of the variables in the 
model measuring VE. We included age, sex, presence of chronic conditions, pregnancy and obesity 
where applicable, and date of symptom onset as a priori confounding variables in the model. All 
other potential confounders were included in the model if they changed the VE point estimate by 5% 
(absolute percentage). Age and onset time were modelled as a restricted cubic spline with knots 
specified according to Harrel (19).  
We measured current season VE for each type/subtype and season. To study the effects of previous 
vaccination on current season vaccination we conducted two analyses. 
First we conducted a stratified analysis in which we measured current season VE among individuals 
vaccinated and unvaccinated in the previous season.  
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In a second analysis, we used unvaccinated in both seasons as a reference to compare VE between 
vaccinated in current season only, vaccinated in previous season only, and vaccinated in both 
seasons, using a mutually exclusive indicator variable.  We refer to this analysis as the indicator 
analysis. 
For each influenza type/subtype, we used seasons and sites for which I-MOVE MCCS included at least 
four cases of this influenza type/subtype per analysed stratum. We deemed sample size too small to 
attempt an analysis if there were fewer than 50 cases in the pooled study analysis. If the 10 events 
per variable (EPV) rule was violated [Peduzzi et al, J Clin Epidemiol. 1996], we carried out a sensitivity 
analysis using Firth’s method of penalized logistic regression to check for small sample bias. 
 
Results 
Recruitment 
From season 2011/12 to 2016/17, we included between six (in 2013/14) and 12 (in 2015/16, 
2016/17) sites in the pooled analysis of our multicentre study (Table 1). GPs enrolled 10,831 ILI 
patients, aged nine years or older, belonging to the groups targeted for influenza vaccination. Of 
these, we excluded 368 individuals with missing information on current season vaccination and 405 
on previous vaccination. The proportion of individuals excluded due to missing information on 
current or previous season was 6.9% among cases and 7.3% among controls (Fisher exact test, 
p=0.365). The median age was 63 and 60 years for those with missing and complete information for 
vaccination status respectively (p<0.001).  
Of the 10,058 ILI individuals with information on current and previous season vaccination status, 19 
(0.2%) had influenza virus co-infections reported and were considered in more than one influenza 
type/subtype analyses. We therefore included 5532 (54.9%) ILI patients negative for all influenza 
viruses and 941 (9.3%), 2645 (26.2%) and 959 (9.5%) positive for influenza virus A(H1N1)pdm09, 
A(H3N2), and B, respectively (Table 2).  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The median age was 54, 55, 63 and 61 years among influenza A(H1N1)pdm09, influenza B cases, 
influenza A(H3N2) cases and controls respectively.  
 
The proportion of vaccinated with current season vaccine was 32% among controls and 20%, 31%, 
and 21% among influenza A(H1N1)pdm09, A(H3N2)  and B cases, respectively (Table 2). The 
proportion of quadrivalent vaccines used among those with known vaccine brand was <1%. 
In each analysis, among cases and controls, less than 6% were vaccinated in the current season only 
and less than 8% in the previous season only. More than 60% of cases and controls were 
unvaccinated in both current and previous season and less than 27% were vaccinated in both 
seasons (Table 2).  
The proportion of controls 65 years and older among those vaccinated in both seasons was 64.3% 
compared to 44.2%, 42.0% and 27.1% among those vaccinated in the previous season only, 
vaccinated in the current season only and not vaccinated in either season (Table 3). 
Vaccine effectiveness 
We included four influenza seasons for the influenza A(H1N1)pdm09 and A(H3N2) analysis and two 
for the influenza B analysis (Table 4). 
Current season VE 
The current season adjusted VE against Influenza A(H1N1)pdm09 ranged from 33% (95% CI: 10 to 51) 
in 2015/16 to 56% (95% CI: 22 to 75) in 2013/14.  
Current season VE against influenza A(H3N2) ranged from 16% (95%CI: -10 to 36) in 2014/15 to 38% 
in 2013/14 (95% CI: -1 to 62), and against B it ranged from 20% (95% CI: -14 to 43) in 2015/16 to 51% 
(95% CI: 27 to 68) in 2012/13 (Table 1).  
 
Stratified analysis, current season VE according to previous season vaccination  
Influenza A(H1N1)pdm09. Among those not vaccinated in the previous season, the current season 
adjusted VE ranged from 51% (95% CI: -29 to 81) in 2013/14 to 63% (95% CI: 6 to 85) in 2015/16. We 
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could only compute current season adjusted VE among those vaccinated in the previous season for 
one season due to the high proportion of individuals vaccinated in both current and previous season. 
In the 2015-16 season, the VE against A(H1N1)pdm09 among those vaccinated in the previous season 
was -38 (95% CI: -179 to 31) (Table 1). 
Influenza A(H3N2). We could compute VE stratified by previous vaccination status in three out of the 
four seasons. In these three seasons, current season VE point estimate among those vaccinated in 
previous season was negative (-68%, - 21% and -19%  in 2011/12, 2014/15, 2016/17 respectively) and 
lower than among those unvaccinated in previous season (33%, 48%, 46% in 2011/12, 2014/15, 
2016/17 respectively) (Table 1). 
Influenza B. Among those not vaccinated in previous season, current season adjusted VE ranged 
from 43% (95% CI: -34 to 76) in 2012/13 to 61% (95% CI: 20 to 81) in 2014/15. The current season VE 
among those vaccinated in the previous season ranged from 34% to 48% (Table 1). 
 
Indicator analysis, using those unvaccinated in both seasons as reference 
Influenza A(H1N1)pdm09  
In 2013/14, the VE point estimate for vaccination in both current and previous season, was higher 
than for vaccination in the current season only (Table 5). In the other three seasons VE point 
estimates for vaccination in both seasons were lower than for vaccination in current season only. VE 
point estimates for vaccination in previous season only was 35% in 2014/15 and 47% in 2015/16 and 
negative in both 2012/13 and 2013/14 (Table 5).   
Influenza A(H3N2) 
In 2013/14, 2014/15 and 2016/17, VE point estimates for vaccination in both current and previous 
season were lower than for vaccination in current season only (Table 5). In 2011/12, VE point 
estimates for those two groups were similar (less than 9% absolute difference). VE point estimates, 
for vaccination in previous season only, ranged from 15% to 60% (Table 5).  
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Influenza B 
In 2012/13, the VE point estimate for vaccination in both current and previous season was higher 
than for vaccination in current season only.  In 2014/15 and 2015/16, VE point estimates for 
vaccination in both seasons were lower than for vaccination in the current season only. VE point 
estimates for vaccination in the previous season only was 4% in 2012/13 and negative for the other 
two seasons (Table 5).  
Sensitivity analysis 
Where the EPV < 10, penalised and standard logistic regression VE estimates did not differ by more 
than 6.5% absolute, with an average of 3.4%, for both the stratified and indicator analyses, indicating 
little bias due to sparse data. 
Discussion 
Our results suggest that, based on the stratified analysis results, previous vaccination may have an 
effect on current season VE among the population targeted for influenza vaccination. Despite low 
precision, the current season VE point estimates against influenza A(H1N1)pdm09 in the 2015-16 
season and against influenza A(H3N2) in the seasons where calculable (2011-12, 2014-15, 2016-17) 
were lower among those vaccinated in the previous season than among those not vaccinated in 
previous season. These VE estimates were less than 0%, suggesting a negative effect of previous 
vaccination.  This was not seen against influenza B, where the VE among those previously vaccinated 
was positive, indicating an effect of current vaccination additionally to any residual protection from 
previous vaccination. However precision is low for most of these analyses and the current VE among 
those vaccinated previously was not possible to compute, so we cannot draw conclusions on a 
consistent or common pattern for the three influenza types/subtypes. 
Individuals unvaccinated in both seasons are at a higher risk of laboratory-confirmed influenza than 
in any vaccination scenario (current season only, last season only, both seasons). This would suggest 
that, even if the effect can be limited in some seasons, whatever the past vaccination scenario, being 
vaccinated in a season is always beneficial.  
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In the 2011/12 and 2016/17 influenza A(H3N2) seasons and in the 2015-16  influenza A(H1N1)pdm09 
analysis, the VE point estimates and confidence intervals among those vaccinated only in the 
previous season suggest a protective effect of previous season vaccine for those subtypes. This is 
consistent with the duration of protection observed for A(H1N1)pdm09, but contradictory to the 
short duration of protection for A(H3N2)(20). 
Our study has several limitations. Even though our analysis is restricted to the target group for 
vaccination, the vaccination coverage is still low (6%, 7%, and 26% of controls vaccinated in current 
season only, in previous season only and in both seasons, respectively). This results in a low precision 
and high variability of the results.  
Past infections and natural immunity play an important role in the protection against circulating 
influenza strains (21,22) and may strengthen the response to subsequent vaccines (23). Measuring 
immunity conferred by past infection is challenging. An immunological study suggests that the 
response to inactivated influenza vaccines is lower among individuals previously vaccinated than  
among individuals with previous natural influenza A(H1N1)pdm09 virus infection (24). In a hospital-
based study in Japan a negative effect of previous vaccination on current season vaccine 
effectiveness was observed in individuals not infected but not in individuals infected with influenza A 
virus in the previous season (8). Individuals in the same age group may have had similar exposure to 
previous circulating influenza viruses resulting in a similar influenza antibody landscape (25–27). In 
our study, the low vaccination coverage and number of cases in some age groups did not allow for 
estimation of results by age group.    
We only collect information on the effect of one previous season vaccination and were not able to 
take into account the role of repeated previous vaccinations. In a study using eight seasons pooled 
data and five previous years of historical vaccination, VE was similar for those vaccinated in the 
current season and those vaccinated in current and previous season (4). However, VE was lower for 
current season in the group of individuals vaccinated at least in two out of five seasons than in 
individuals never vaccinated in the five seasons.  
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We documented the vaccine type for the current season but not for the previous season. Studies 
suggest that the type of vaccine received in current or previous season may influence the effect of 
previous vaccination in current season VE (4,7). In our study, four types of vaccines were used: egg-
derived inactivated subunit, egg-derived inactivated split virion, cell-derived inactivated subunit and 
adjuvanted vaccines (adjuvant used: squalene (MF59) or aluminum phosphate gel). We could not 
stratify VE results by type of current and previous vaccines.  
While the test-negative design attempts to control for bias due to differential healthcare-seeking 
behaviours (28), the study is observational and subject to the usual limitations, in particular 
adequately controlling for confounding.  
 
Results interpretation 
Influenza A(H1N1)pdm09  
The stratified results in the 2015-16 season suggested that the effectiveness of current season 
vaccination against influenza A(H1N1)pdm09 was lower among those vaccinated in the previous 
season. When using unvaccinated in both seasons as reference, VE point estimates for current 
season vaccination only were higher than for both seasons vaccination in three out of the four 
seasons. The positive VE of previous season vaccination only in the 2014/15 and 2015/16 season 
analysis suggest a potential residual effect of vaccination against influenza A(H1N1)pdm09 in these 
seasons. This observation is in line with two recent meta-analysis (11,29) and with the stable 
influenza  A(H1N1)pdm09 VE by time since vaccination observed in the I-MOVE MCCS from 2010/11 
to 2015/16 (20). 
Influenza A(H3N2) 
We observed that in all seasons, A(H3N2) VE point estimates were lower among those vaccinated in 
the previous season than in those unvaccinated in previous season.  
Using unvaccinated in both seasons as reference, VE of various vaccination scenarios varied by 
season.   In 2011/12 and 2013/14 VE point estimates against influenza A(H3N2) were similar for 
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current season vaccination only and both seasons vaccination. In 2011/12, previous and current 
season vaccine strains were antigenically similar but mismatched to one of the co-circulating strains.  
In 2013/14, the circulating strains were antigenically similar to the vaccine strain but different to the 
2012/13 vaccine strain that had egg-adaptation amino acid changes negatively impacting its 
antigenicity (30).   
In 2014/15 VE against influenza A(H3N2) was much lower among those vaccinated in 2013/14 and 
2014/15 than among those vaccinated only in 2014/15. The influenza A(H3N2) vaccine strains in 
2013/14 and 2014/15 were homologous but antigenically different from the drifted virus circulating 
in 2014/15. Even if the precision is low, our results are in accordance with the antigenic distance 
hypothesis (16). In the 2014/15 VE results from Canada (5,10) and from I-MOVE MCCS (not restricted 
to the target population) (6), the point VE estimate among those vaccinated in both 2013/14 and 
2014/15 was negative suggesting that those vaccinated in both seasons were at higher risk of 
influenza A(H3N2) medically-attended influenza than those vaccinated only in 2014/15. In the 
current I-MOVE MCCS analysis restricted to the vaccine target population, the VE point estimate for 
those vaccinated in both seasons was positive but lower than the VE of those vaccinated only in 
2014/15.   
 In 2016/17 the VE point estimate was also lower for those vaccinated in both 2016/17 and 2015/16 
seasons than in those vaccinated only in 2016/17. The antigenic hypothesis may not explain this 
observation as the A(H3N2) circulating strain and the strains included in the 2016/17 and 2015/16 
vaccines were considered antigenically similar. However it is worth noting that in the 2016-17 
season, the  A(H3N2) viruses circulating in Europe underwent considerable genetic changes with new 
subgroups diversifying from the vaccine strains (31).   
 
Influenza B 
The low precision of the VE against influenza B did not allow us to identify any pattern of the effect of 
previous vaccination. However, VE point estimates for vaccination in current season only were 
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always positive and VE point estimates for previous season only vaccination were low or negative. 
We could not measure VE by influenza B lineage which limits interpretation.  
 
Conclusion 
We cannot exclude that being vaccinated the previous season may reduce the VE of the current 
season vaccine, in particular for A(H3N2). However, the positive VE results among those vaccinated 
in current season only and those vaccinated in both seasons in this study suggest that being 
vaccinated in a given season is always beneficial. 
Despite a growing sample size in I-MOVE MCCS, results are still imprecise due to low vaccination 
coverage and to the strong association between being vaccinated in current and previous season. 
The results of the six seasons can only contribute to test hypotheses that try to understand the effect 
of previous vaccination on influenza VE.   
Influenza vaccine effectiveness depends on complex interactions between host (e.g. natural infection 
versus vaccination acquired immunity), agent, and environmental factors (32). Optimum 
measurement and interpretation of influenza seasonal VE would require taking into account many 
parameters including: subtypes, clade, subclades, age, time since vaccination, chronic conditions and 
treatment, duration of protection, vaccine types and brands, natural immunity and previous 
vaccinations.  
So far, the studies presenting the effect of previous seasons influenza vaccinations neither collected 
all this information nor were powered enough to provide precise results. The modifying or 
confounding effect of those parameters would no longer be relevant in terms of public health if the 
influenza vaccine had a high effectiveness.  
Only well powered, population based, long prospective studies would allow understanding the 
immunological response to influenza vaccinations and infections. They could document influenza 
infections, vaccinations and type of vaccines used, cellular and humoral immune status before and 
during each season in vaccinated and unvaccinated, infected and not. A European mechanism of 
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funding such large studies is needed to ensure powerful studies conducted independently from 
funding sources.  
In the context of universal influenza vaccine development, the question is whether results of these 
proposed prospective studies would be available before the next generation of vaccines is accessible.  
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TABLE 1. Vaccine effectivenessa against influenza type/subtype overall and stratified by previous season vaccination, among the target group for 
influenza vaccination, aged 9 years or older, I-MOVE multicentre case–control study, influenza seasons 2011/12–2016/17 (patients with missing 
data on previous vaccination status excluded)  
Type subtype 
Season Study sites 
included 
Current season VE Current season VE 
Among those not vaccinated in previous 
season 
Current season VE 
Among those vaccinated in previous season 
  
  Influenza cases; 
cases vaccinated 
/  controls; 
controls 
vaccinated  VE 95% CI 
Influenza cases; 
cases vaccinated /  
controls; controls 
vaccinated VE 95% CI 
Influenza cases; 
cases vaccinated /  
controls; controls 
vaccinated VE 95% CI 
A(H1N1)pdm09 2012/13 
DE, FR, ES, IE, 
PL, PT, RO 172;27 / 442;138 40.0 0.3-63.9 136;4 / 296;20 62.1 -22.8-88.3 36;23 / 134;111 NC  
 2013/14 
DE, ES,HU, IE, 
PT, RO 123;24 / 371;139 56.2 22.3-75.3 99;7 / 244;28 50.6 -29.1-81.1 24;17 / 122;107 NC  
 2014/15 
DE, ES, FR, 
HU, IE, IT, PL, 
RO, SE 171;31 / 808;246 45.4  12.5-65.9 140;6 / 571;61 62.5 6.3-85.0 31;25 / 230;180 NC  
 2015/16 
DE, ES, FR, 
HU, HR, IE, IT, 
NL, PL, PT, 
RO, SE 454;105 / 1239;390 33.3  9.7-50.8 345;10 / 830;57 61.3 17.4-81.9 109;95 / 409;333 -38.4 -178.8-31.3 
A(H3N2) 2011/12
 
 
FR, ES, HU, IE, 
IT, PT, RO 411;148 / 543;200 25.2   -6.4-47.4 273;21 / 339;36 32.7 -35.8-66.7 138;127 / 204;164 -68.2 -299.3-29.1 
 2013/14
 
 
DE, ES, HU, IE, 
PT, RO 151;48 / 379;139 38.2 -1.3-62.4 106;8 / 252;28 50.1 -30.9-81.0 45;40 / 127;111 NC  
 2014/15 
DE, ES, FR, 
HU, IE, IT, PL, 
PT, RO, SE 587;184 / 918;292 16.0 -10.0-35.9 408;30 / 628;71 47.6 14.2-68.0 179;154 / 289;220 -21.2 -121.2-33.6 
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2016/17 
DE, ES, FR, 
HU, HR, IE, IT, 
NL, PL, PT, 
RO, SE 1345;411/1572;496 21.3 5.7-34.4 921;52 / 1045;91 45.9 21.1-62.9 424;359 / 527;405 -18.5 -73.2-18.9 
B 2012/13
 
 
DE, ES, FR, IE, 
PL, PT, RO 304;55 / 468;145 50.8 26.5-67.0 243;9 / 311;20 43.0 -33.7-75.7 61;46 / 125;97 56.4 -10.0-82.7 
 2014/15
 
 
DE, ES, FR, 
HU, IE, IT, PL, 
PT, RO, SE, 320;65 / 904;288 40.2 14.0-58.4 249;11 / 624;72 60.7 20.3-80.6 71;54 / 269;207 33.8 -50.3-70.8 
 2015/16
 
 
DE, ES, FR, 
HR, HU, IE, IT, 
NL, PL, PT, 
RO, SE 310;77 / 991;311 19.6 -13.7-43.1 220;9 / 674;45 45.9 -18.3-75.2 90;68 / 314;263 52.2 1.8-76.7 
DE: Germany; ES: Spain; FR: France; HR: Croatia; HU, Hungary; IE: Ireland; IT: Italy; NL: Netherlands; PL: Poland; PT: Portugal; RO: Romania; SE: Sweden  
VE: Vaccine effectiveness 
CI: Confidence Intervals 
Casesvacc: cases vaccinated 
Controlsvacc: controls vaccinated  
NC: Not computed since sample size did not allow to include study site as fixed effect. 
a VE estimates adjusted by study site, season, age (restricted cubic splines), onset date (restricted cubic splines), chronic condition, sex. 
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Table 2. Characteristics for influenza A(H1N1)pdm09, A(H3N2) and influenza B cases, and controls 
belonging to the target group for influenza vaccination, aged 9 years or older, I-MOVE 2011/12 – 
2016/17 
Characteristics 
Number of 
 test-negative 
controlsa /total n 
(%) 
 
Number of influenza 
A(H1N1)pdm09 
casesb,c /total n(%) 
Number of influenza 
A(H3N2) cases 
b,d/total n(%) 
Number of 
influenza B cases 
c,d /total n(%) 
Median age (years) 61.0 54.0 63.0 55.0 
Missing 14 5 4 8 
Age groups      
9-14 194/5518 (3.5) 33/936 (3.5) 130/2641 (4.9) 97/951 (10.2) 
15-64 3183/5518 (57.7) 662/936 (70.7) 1333/2641 (50.5) 572/951 (60.1) 
≥ 65 2141/5518 (38.8) 241/936 (25.7) 1178/2641 (44.6) 282/951 (29.7) 
Sex     
Female 3249/5515 (58.9) 533/935 (57.0) 1469/2637 (55.7) 511/955 (53.5) 
Missing 17 6 8 4 
Days between onset 
of symptoms and 
swabbing 
    
0 315/5532 (5.7) 26/941 (2.8) 108/2645 (4.1) 29/959 (3.0) 
1 1552/5532 (28.1) 311/941 (33) 874/2645 (33) 245/959 (25.5) 
2 1519/5532 (27.5) 312/941 (33.2) 847/2645 (32) 301/959 (31.4) 
3 1006/5532 (18.2) 163/941 (17.3) 493/2645 (18.6) 227/959 (23.7) 
4-7 1140/5532 (20.6) 129/941 (13.7) 323/2645 (12.2) 157/959 (16.4) 
Current season 
influenza vaccination     
Not vaccinated or 
vaccinated < 15 days 
before ILI onset 3771/5532 (68.2) 749/941 (79.6) 1820/2645 (68.8) 759/959 (79.1) 
Vaccinated 1761/5532 (31.8) 192/941 (20.4) 825/2645 (31.2) 200/959 (20.9) 
Previous season 
influenza vaccination     
Not vaccinated in 
current and previous 
3386/5532 (61.2) 708/941 (75.2) 1708/2645 (64.6) 704/959 (73.4) 
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season or vaccinated 
in current season <15 
days before onset 
Current season 
vaccination only 324/5532 (5.9) 27/941 (2.9) 116/2645 (4.4) 30/959 (3.1) 
Previous season 
vaccination only 385/5532 (7.0) 41/941 (4.4) 112/2645 (4.2) 55/959 (5.7) 
Current and previous 
season vaccination 1437/5532 (26.0) 165/941 (17.5) 709/2645 (26.8) 170/959 (17.7) 
Seasonal vaccination 
type 
    
Not vaccinated or 
vaccinated <15 days 
before onset 3771/5532 (68.2) 749/941 (79.6) 1820/2645 (68.8) 759/959 (79.1) 
Egg-derived 
inactivated subunit 521/5532 (9.4) 61/941 (6.5) 244/2645 (9.2) 69/959 (7.2) 
Egg-derived 
inactivated split virion  638/5532 (11.5) 97/941 (10.3) 309/2645 (11.7) 68/959 (7.1) 
Adjuvanted 351/5532 (6.3) 8/941 (0.9) 149/2645 (5.6) 17/959 (1.8) 
Cell-derived 
inactivated subunit 10/5532 (0.2) 0/941 (0.0) 7/2645 (0.3) 3/959 (0.3) 
Live attenuated 
influenza vaccine 0/5532 (0.0) 0/941 (0.0) 1/2645 (0.0) 0/959 (0.0) 
Unknown vaccine type 241/5532 (4.4) 26/941 (2.8) 115/2645 (4.3) 43/959 (4.5) 
At least one chronic 
condition 4105/5436 (75.5) 699/931 (75.1) 1858/2612 (71.1) 700/945 (74.1) 
Missing 96 10 33 14 
At least one 
hospitalisation in the 
previous 12 months 
for chronic conditions 352/5075 (6.9) 48/834 (5.8) 128/2462 (5.2) 51/841 (6.1) 
Missing 457 107 183 118 
Study sites     
Croatia 100/5532 (1.8) 14/941 (1.5) 60/2645 (2.3) 18/959 (1.9) 
France 524/5532 (9.5) 126/941 (13.4) 390/2645 (14.7) 168/959 (17.5) 
Germany 1397/5532 (25.3) 173/941 (10.3) 505/2645 (19.1) 186/959 (19.4) 
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a Controls from “any influenza” analysis used. 
b 1 influenza case coinfected for both influenza A(H3N2) and for influenza A(H1N1)pdm09 was included in the analysis. 
c 9 influenza cases coinfected for both influenza B and for influenza A(H1N1)pdm09 were included in the analysis. 
d 9 influenza cases coinfected for both influenza B and for influenza A(H3N2) were included in the analysis. 
 
  
Hungary 949/5532 (17.2) 33/941 (2.0) 276/2645 (10.4) 47/959 (4.9) 
Ireland 222/5532 (4) 65/941 (4.2) 130/2645 (4.9) 52/959 (5.4) 
Italy 476/5532 (8.6) 50/941 (3.3) 222/2645 (8.4) 56/959 (5.8) 
Poland 340/5532 (6.1) 70/941 (4.8) 116/2645 (4.4) 59/959 (6.2) 
Portugal 402/5532 (7.3) 95/941 (6.7) 175/2645 (6.6) 55/959 (5.7) 
Romania 179/5532 (3.2) 74/941 (5.5) 82/2645 (3.1) 53/959 (5.5) 
Spain 652/5532 (11.8) 197/941 (9.8) 592/2645 (22.4) 240/959 (25.0) 
Sweden 113/5532 (2) 8/941 (0.4) 43/2645 (1.6) 13/959 (1.4) 
The Netherlands 178/5532 (3.2) 36/941 (2.0) 54/2645 (2.0) 12/959 (1.3) 
Season     
2011-12 600/5532 (10.8) - 411/2645 (15.5) - 
2012-13 517/5532 (9.3) 181/941 (19.2) 114/2645 (4.3) 313/959 (32.6) 
2013-14 425/5532 (7.7) 123/941 (13.1) 153/2645 (5.8) - 
2014-15 988/5532 (17.9) 174/941 (18.5) 608/2645 (23.0) 324/959 (33.8) 
2015-16 1357/5532 (24.5) 463/941 (49.2) - 322/959 (33.6) 
2016-17 1645/5532 (29.7) - 1359/2645 (51.4) - 
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Table 3: Characteristics of test-negative controlsa by vaccination history, among the target 
population for influenza vaccination, aged 9 years or more, I-MOVE 2011/12 – 2016/17. 
Characteristics 
Not vaccinated in 
either current or 
previous season 
Vaccinated in 
current season 
Vaccinated in previous 
season only 
Vaccinated in both 
seasons 
Median age (years) 56.0 62.0 62.0 69.0 
Missing 11 0 0 3 
Age groups      
9-14 153/3375 (4.5) 10/324 (3.1) 8/385 (2.1) 23/1434 (1.6) 
15-64 2307/3375 (68.4) 178/324 (54.9) 207/385 (53.8) 491/1434 (34.2) 
≥ 65 915/3375 (27.1) 136/324 (42.0) 170/385 (44.2) 920/1434 (64.2) 
Missing 11 0 0 3 
Sex     
Female 1396/3373 (41.4) 128/324 (39.5) 159/385 (41.3) 583/1433 (40.7) 
Male 1977/3373 (58.6) 196/324 (60.5) 226/385 (58.7) 850/1433 (59.3) 
Missing 13 0 0 4 
Days between onset 
of symptoms and 
swabbing 
    
0 212/3386 (6.3) 17/324 (5.2) 17/385 (4.4) 69/1437 (4.8) 
1 1021/3386 (30.2) 89/324 (27.5) 105/385 (27.3) 337/1437 (23.5) 
2 958/3386 (28.3) 76/324 (23.5) 109/385 (28.3) 376/1437 (26.2) 
3 582/3386 (17.2) 59/324 (18.2) 63/385 (16.4) 302/1437 (21.0) 
4-7 613/3386 (18.1) 83/324 (25.6) 91/385 (23.6) 353/1437 (24.6) 
At least one chronic 
condition 2425/3315 (73.2) 253/317 (79.8) 308/380 (81.1) 1119/1424 (78.6) 
Missing 71 7 5 13 
At least one 
hospitalisation in the 
previous 12 months 
for chronic 
conditions 171/3104 (5.5) 20/294 (6.8) 33/346 (9.5) 128/1331 (9.6) 
Missing 282 30 39 106 
Season     
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Characteristics 
Not vaccinated in 
either current or 
previous season 
Vaccinated in 
current season 
Vaccinated in previous 
season only 
Vaccinated in both 
seasons 
2011-12 351/3386 (10.4) 39/324 (12.0) 42/385 (10.9) 168/1437 (11.7) 
2012-13 325/3386 (9.6) 24/324 (7.4) 37/385 (9.6) 131/1437 (9.1) 
2013-14 258/3386 (7.6) 32/324 (9.9) 19/385 (4.9) 116/1437 (8.1) 
2014-15 607/3386 (17.9) 75/324 (23.1) 72/385 (18.7) 234/1437 (16.3) 
2015-16 849/3386 (25.1) 59/324 (18.2) 90/385 (23.4) 359/1437 (25.0) 
2016-17 996/3386 (29.4) 95/324 (29.3) 125/385 (32.5) 429/1437 (29.9) 
a Controls from “any influenza” analysis used. 
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Table 4.  Predominant influenza strains circulating and influenza strains included in the vaccines in Europe by influenza virus type/subtype and season, 2012/13-2016/17 
Type/subtype Season  Vaccine strains Main circulating strain(s) in Europe 
 Previous season vaccine strain Current season vaccine strain  
 
A(H1N1)pdm09 2012/13 A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like 
 2013/14
 
 A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like 
 2014/15 A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like 
 2015/16 A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like A/California/7/2009 (H1N1)-like 
A(H3N2) 2011/12 
 
A/Perth/16/2009(H3N2)-like A/Perth/16/2009(H3N2)-like A/Perth/16/2009(H3N2)-like 
 A/Victoria/361/2011(H3N2)like 
 2013/14 A/Victoria/361/2011(H3N2)-like
a
 A/Texas/50/2012(H3N2)-like  A/Texas/50/2012(H3N2)-like  
 2014/15 A/Texas/50/2012(H3N2)-like A/Texas/50/2012(H3N2)-like A/Switzerland/9715293/2013 (H3N2)-like 
 2016/17 A/Switzerland/9715293/2013 (H3N2)-like virus A/Hong Kong/4801/2014 (H3N2)-like A/Hong Kong/4801/2014 (H3N2)-like 
B 2012/13 B/Brisbane/60/2008-like (Victoria) B/Wisconsin/61/2010-like (Yamagata) B/Massachusetts/2/2012-like (Yamagata) 
 2014/15 B/Massachusetts/2/2012-like (Yamagata) B/Massachusetts/2/2012-like (Yamagata) B/Phuket/3073/2013-like (Yamagata)  
 2015/16 B/Massachusetts/2/2012-like (Yamagata) B/Phuket/3073/2013-like (Yamagata) B/Brisbane/60/2008-like(Victoria) 
Sources: Sources: http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en/ [accessed 15 March 2018]; https://ecdc.europa.eu/en/seasonal-
influenza/surveillance-and-disease-data/influenza-virus-characterisation [accessed 15 March 2018] 
a An egg adaptative mutation in the egg propagated A/Victoria/361/2011 modified the antigenic characteristics of the vaccine strain that resulted  in a strain antigenically different from the circulating Texas 
viruses 
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Table 5. Vaccine effectivenessa for vaccination in current season only, previous season only or both seasons among the target population for influenza vaccination, aged 9 
years or more, by influenza type/subtype and influenza strains circulating and included in the current and previous season vaccine, I-MOVE 2011/12 – 2016/17.  
Type/subtype Season Vaccinated current season only Vaccinated previous season only Vaccinated both seasons 
  cases (% of all 
cases)/controls (% of 
all controls) 
VE 95% CI cases (% of all 
cases)/controls (% of 
all controls) 
VE 95% CI cases (% of all 
cases)/controls (% of 
all controls) 
VE 95% CI 
A(H1N1)pdm09 2012/13 4 (2.3) / 20 (4.5) 59.7 -28.9-87.4 13 (7.6) / 28 (6.3) -7.9 -135.0-50.4 23 (13.4) / 118 (26.7) 33.8 -15.4-62.1 
 2013/14
 
 7 (5.7) / 28 (7.5) 40.3 -51.7-76.5 7 (5.7) / 16 (4.3) -7.8 -199.4-61.2 17 (13.8) / 111 (29.9) 60.6 24.3-79.5 
 2014/15 6 (3.5) / 61 (7.5) 60.7 2.7-84.1 6 (3.5) / 52 (6.4) 35.1 -63.0-74.2 25 (14.6) / 185 (22.9) 42.4 3.2-65.7 
 2015/16 10 (2.2) / 57 (4.6) 60.4 15.9-81.3 14 (3.1) / 76 (6.1) 46.6 -2.0-72.1 95 (20.9) / 333 (26.9) 31.8 5.7-50.6 
A(H3N2) 2011/12 
21 (5.1) / 36 (6.6) 37.8 -24.9-69.1 11 (2.7) / 40 (7.4) 59.8 11.2-81.8 127 (30.9) / 164 (30.2) 29.4 -3.2-51.7 
 2013/14 8 (5.3) / 28 (7.4) 44.6 -38.8-77.9 5 (3.3) / 16 (4.2) 28.7 -133.3-78.2 40 (26.5) / 111 (29.3) 39.1 -4.1-64.4 
 2014/15 30 (5.1) / 71 (7.7) 47.5 14.8-67.6 25 (4.3) / 69 (7.5) 15.1 -45.7-50.5 154 (26.2) / 221 (24.1) 5.2 -27.5-29.5 
 2016/17 52 (3.9) / 91 (5.8) 45.8 21.5-62.6 65 (4.8) / 122 (7.8) 30.8 2.1-51.1 359 (26.7) / 405 (25.8) 18.8 1.0-33.3 
B 2012/13 
 9 (3.0) / 20 (4.3) 39.4 -42.7-74.3 15 (4.9) / 32 (6.8) 4.0 -93.1-52.3 46 (15.1) / 125 (26.7) 53.0 27.5-69.5 
 2014/15 
 11 (3.4) / 72 (8.0) 59.1 17.1-79.8 17 (5.3) / 64 (7.1) -6.2 -103.3-44.5 54 (16.9) / 216 (23.9) 32.8 -0.3-54.9 
 2015/16 
 9 (2.9) / 45 (4.5) 46.6 -17.0-75.7 22 (7.1) / 51 (5.1) -37.5 -152.9-25.3 68 (21.9) / 266 (26.8) 9.4 -31.7-37.6  
 
VE: Vaccine effectiveness 
CI: Confidence interval 
Ref: reference 
a VE estimates adjusted by study site, season, age (restricted cubic splines), onset date (restricted cubic splines), chronic condition, sex.
